Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term lung-cancer. Found 54 abstracts

no pagination
Lara H, Wang YH, Beltran AS, Juarez-Moreno K, Yuan XN, Kato S, Leisewitz AV, Fredes MC, Licea AF, Connolly DC, Huang L, Blancafort P. Targeting Serous Epithelial Ovarian Cancer with Designer Zinc Finger Transcription Factors. Journal of Biological Chemistry. 2012 Aug;287(35):29873-86.   PMCID: PMC3436144
Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecologic Oncology. 2012 Nov;127(2):345-50.
Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecologic Oncology. 2012 Nov;127(2):345-50.   PMCID: PMC3518448
Thunnissen E, Beasley MB, Borczuk AC, Brambilla E, Chirieac LR, Dacic S, Flieder D, Gazdar A, Geisinger K, Hasleton P, Ishikawa Y, Kerr KM, Lantejoul S, Matsuno Y, Minami Y, Moreira AL, Motoi N, Nicholson AG, Noguchi M, Nonaka D, Pelosi G, Petersen I, Rekhtman N, Roggli V, Travis WD, Tsao MS, Wistuba I, Xu HD, Yatabe Y, Zakowski M, Witte B, Kuik DJ. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Modern Pathology. 2012 Dec;25(12):1574-83.   PMCID: not NIH funded
Van Cleave JH, Egleston BL, Bourbonniere M, Cardone L, McCorkle R. Functional Status in Older Women Following Gynecological Cancer Surgery: Can Choice of Measure Influence Evidence for Clinical Practice?. Geriatric Nursing. 2012 Mar;33(2):118-26.   PMCID: PMC 3549266
Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu ZH, Watson JC, Weiner LM, Cohen SJ. Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology-Cancer Clinical Trials. 2011 Feb;34(1):70-5.   PMCID: PMC3030655
Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecologic Oncology. 2011 Apr;121(1):230-8.   PMCID: not NIH funded
Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG, Lankes HA. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study. Gynecologic Oncology. 2011 May;121(2):303-8.   PMCID: PMC3081894
Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, Capanu M, Miron B, Klimstra D. A Phase 2 Trial of Erlotinib in Patients With Previously Treated Squamous Cell and Adenocarcinoma of the Esophagus. Cancer. 2011 Apr;117(7):1409-14.   PMCID: PMC3116987
Van Cleave JH, Egleston BL, Bourbonniere M, McCorkle R. Combining Extant Datasets with Differing Outcome Measures Across Studies of Older Adults after Cancer Surgery. Research in Gerontological Nursing. 2011 Jan;4(1):36-46.   PMCID: PMC3263316
Abramowitz MC, Li TY, Morrow M, Anderson PR, Bleicher RJ, Goldstein LJ, Swaby R, Nicoloau N, Freedman GM. History of Smoking is Associated with Younger Age at Diagnosis of Breast Cancer. Breast Journal. 2010 Jul;16(4):344-9.   PMCID: not NIH funded
Golovine K, Makhov P, Uzzo RG, Kutikov A, Kaplan DJ, Fox E, Kolenko VM. Cadmium down-regulates expression of XIAP at the post-transcriptional level in prostate cancer cells through an NF-kappa B-independent, proteasome-mediated mechanism - art. no. 183. Molecular Cancer. 2010 Jul;9:183.   PMCID: PMC3044330
Haenssen KK, Caldwell SA, Shahriari KS, Jackson SR, Whelan KA, Klein-Szanto AJ, Reginato MJ. ErbB2 requires integrin alpha 5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells. Journal of cell science. 2010 Apr;123(8):1373-82.   PMCID: not NIH funded
Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK. Plasma Cell-Free DNA in Ovarian Cancer An Independent Prognostic Biomarker. Cancer. 2010 Apr;116(8):1918-25.   PMCID: PMC2854845
Xu QY, He ZJ, Fan JJ, Hamilton RJ, Chen Y, Ma CM, Xing L. Registration of on-board X-ray images with 4DCT: A proposed method of phase and setup verification for gated radiotherapy. Physica Medica. 2010 Jul;26(3):117-25.   PMCID: Not required
Chen JQ, Russo J. ER alpha-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches. Biochimica Et Biophysica Acta-Reviews on Cancer. 2009 Dec;1796(2):162-75.   PMCID: PMC2937358
Dupart JJ, Trent JC, Lee HY, Hess KR, Godwin AK, Taguchi T, Zhang W. Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro - art. no. 99. Molecular Cancer. 2009 Nov;8:99.   PMCID: PMC2780392
Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, O'Bryant C, Hariharan S, Diab S, Fox NL, Miceli R, Eckhardt SG. Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study. Journal of Clinical Oncology. 2009 Sep;27(26):4413-21.   PMCID: not NIH funded
Barsevick AM, Whitmer K, Nail LM, Beck SL, Dudley WN. Symptom cluster research: Conceptual, design, measurement, and analysis issues. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2006 Jan;31(1):85-95.
Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology. 2006 Jan;24(1):16-24.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term lung-cancer

lung-cancer expression epithelial-cells tumors gefitinib clinical-trials intervention factor receptor colorectal-cancer kinase inhibitor advanced breast-cancer endothelial-cells mutations breast-cancer her2 1994 corkle r-research in nursing & health-v17-p243 epidermal-growth-factor gene-expression tyrosine kinase inhibitor pik3ca mutations growth-factor receptor home care therapy Epidermal growth factor receptor Endometrial cancer-Mutation-Lapatinib-Tyrosine kinase inhibitor enrollment adults Setup verification platinum-resistant induction portal images triple angiokinase inhibitor quality of life combination patient setup quantification Clinical Neurology marker sleep quality index tumor-necrosis-factor plus gemcitabine signal-transduction tumor-suppressor gene 1989 corkle r-cancer-v64-p1375 form health survey calculations information apoptosis induction k-ras activation distress igfbp-3 family time tumor-tracking health survey sf-36 apo2l tyrosine kinases tobacco smoking cell-cycle arrest apoptosis-inducing ligand pancreatic adenocarcinoma squamous cancer esophageal cancer-erlotinib-response evaluation plasma-levels ct classification factor libraries family kinases inventory symptom management progesterone-receptor interleukin-2 breast-cancer cells epidemiology outpatients 4DCT smoking serum dna association fibroblast-growth-factor Ovarian cancer microRNAs EGFR-Therapeutic approaches for TN-breast cancer-Triple negative breast cancer redox regulation 1997 ang ch-phys med rehabil sta-v11-p397 prostate-cancer cells Cisplatin factors atfs ebp-delta gastroesophageal junction coagulation estrogen-receptor-beta uterine cervix radiation-therapy ErbB2 Integrin alpha 5-Her2-Src-Bim-Anoikis-3D culture-Epithelial-Cancer monoclonal-antibody c225 phase-ii trial system cell symptom clusters elderly cancer-patients beta receptor CXC chemokine Breast cancer-CXCL8-ER alpha-ER beta-Estrogen carcinogenesis-GRCP-30 vhl benign carcinomas women patients trail mouse model breast cancer metaanalysis fiducial markers symptoms cigarette-smoking growth-factor General & Internal Medicine chemotherapy Anti-angiogenic therapy angiogenesis in-vitro death receptors functional status pain functional-characterization nuclear-localization decoy receptors barr-virus dna 2-stage designs interferon Cervical cancer iap respiratory motion c-src survival Bevacizumab human monoclonal-antibody real-time polymerase chain reaction cell-free DNA-prognosis-ovarian cancer-biomarker 1994 horney ca-medical care-v32-p40 nasopharyngeal carcinoma framework passive smoking prognostic-factors epithelial ovarian imatinib mesylate depression nurses health population outcomes sf-36 bevacizumab gynecologic-oncology-group circulating endothelial-cells zinc
Last updated on Wednesday, February 05, 2020